Effect of the GSK2245035 on the Allergen-induced Asthmatic Response

Inclusion Criteria * Between 18 and 65 years of age inclusive, at the time of signing the informed consent. * Diagnosis of asthma, as defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation for at least 6 months prior to screening * Current asthma therapy. Intermittent short-acting beta-agonist (SABA) alone (on average for no more than 2 days per week) * Positive skin prick test (3 mm or more greater than negative control) to common perennial or seasonal aeroallergen(s) (i.e., house dust mite, cat dander, grass pollen) at screening * Pre-bronchodilator FEV1 \> 70 % predicted normal at Screening Visit 1 * EAR with \>=20 % FEV1 decrease between 5 and 30 minutes after the final allergen concentration is obtained at the screening bronchial allergen challenge (BAC) (decreases relative to the saline) * LAR with three FEV1 decreases of \>= 15 % between 4 and 10 hours after the final allergen concentration is obtained at the screening bronchial allergen challenge, with two FEV1 decreases being at consecutive time points (decreases relative to the saline) * Subjects who are current non-smokers (defined as no use of any tobacco products in the 6-month period preceding the screening visit) and have a pack history of \< 10 pack years. Number of pack years = (number of cigarettes per day/20) x number of years smoked * Bodyweight \>= 45kilograms …